Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancerLucio Crinò, Angelo Delmonte, Giuseppe Bronte et al.|Lung Cancer|2019Cited by 158
Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal CancerFausto Petrelli, Alberto F. Sobrero, Roberto Labianca et al.|JAMA Oncology|2020Cited by 49
Observational study on quality of life, safety, and effectiveness of first‐line cetuximab plus chemotherapy in <i><scp>KRAS</scp></i> wild‐type metastatic colorectal cancer patients: the ObservEr StudyCarmine Pinto, Francesco Di Costanzo, Francesca Di Fabio et al.|Cancer Medicine|2016Cited by 26
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trialGerardo Rosati, Giordano Beretta, Sara Lonardi et al.|European Journal of Cancer|2021Cited by 15
Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trialMaria Di Bartolomeo, Filippo Pietrantonio, Monica Niger et al.|BMC Cancer|2019Cited by 15